HOME >> MEDICINE >> NEWS
Miniature implanted devices could treat epilepsy, glaucoma
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Miniature implanted devices could treat epilepsy glaucoma

(Date:4/21/2015)... The report “Dermatitis – ... on the therapeutic development for Dermatitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Dermatitis ...
(Date:4/21/2015)... Edward Avalos, USDA Under Secretary for Marketing and ... the California Department of Food and Agriculture, have been ... Conference: The Future of Local Food, conference organizers announced ... known experts intensifies an already strong line-up of sustainable ... to speak at the June 11-13 event. ...
(Date:4/21/2015)... Wojo Nutrition announces Abe’s ... its healthiest, will carry Wojo Nutrition's lines of single ... Nutrition, they’ve launched a revolution in the vitamin industry ... meet their multifaceted goals. Their line of single serving ... has been specially formulated to be as unique as ...
(Date:4/21/2015)... has released a new blog post explaining the ... , Comprehensive auto insurance is a complex policy ... limit can also be high and the premiums are ... against fire damage, vandalism, theft and from many other ... and it can help drivers find the right type ...
(Date:4/21/2015)... Health Advocate™, Inc., the nation’s leading ... West Corporation, is hosting a complimentary webinar on April ... benefits of offering this service to employees. , As ... their healthcare, it is critical that they have access ... their health benefits. Health advocates can play a significant ...
Breaking Medicine News(10 mins):Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 2Health News:USDA Under Secretary, former CA Agriculture Director to Address 2nd Annual “GrowRIVERSIDE” Conference in June 3Health News:Wojo Nutrition Announces their Lines of Single Serving Liquid Vitamins will be Available for Purchase online at Abesmarket.com Beginning in May 2Health News:Comprehensive Auto Insurance Is An Important But Complex Policy 2Health News:Health Advocate Webinar Discusses Benefits of Health Advocacy 2
(Date:4/21/2015)... SPRING, Md. , April 21, 2015 /PRNewswire-USNewswire/ ... told the U.S. Food and Drug Administration that ... worked effectively for the last 25 years to ... to safe homeopathic medicines. AAHP, the industry,s trade ... and consumers of homeopathic medicines to engage in ...
(Date:4/21/2015)... 21, 2015 Delcath Systems, Inc. (NASDAQ: ... Trial Authorizations (CTAs) filed with the U.K.,s ... and Germany,s Federal Institute for ... the Company,s global Phase 2 program for the treatment ... or HCC), to include a cohort of patients with ...
(Date:4/21/2015)... , April 21, 2015   Mast ... biopharmaceutical company leveraging its molecular adhesion and sealant ... sickle cell disease, heart failure, and arterial disease, ... EPIC study of its lead product ... surpassed the halfway point. Consistent with prior guidance, ...
Breaking Medicine Technology:Speakers at FDA Hearing Praise Success of Homeopathic Regulatory Framework 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 2Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 3Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic Cholangiocarcinoma 4Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 2Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 3Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 4Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 5
Cached News: